Cargando…
The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations
In March 2011, a Final Rule for expedited reporting of serious adverse events took effect in the United States for studies conducted under an Investigational New Drug (IND) application. In December 2012, the U.S. Food and Drug Administration (FDA) promulgated a final Guidance describing the operatio...
Autores principales: | Wittes, Janet, Crowe, Brenda, Chuang-Stein, Christy, Guettner, Achim, Hall, David, Jiang, Qi, Odenheimer, Daniel, Xia, H. Amy, Kramer, Judith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606817/ https://www.ncbi.nlm.nih.gov/pubmed/26550466 http://dx.doi.org/10.1080/19466315.2015.1043395 |
Ejemplares similares
-
Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule
por: Kramer, Judith M., et al.
Publicado: (2014) -
FDA expedited approval and implications for rational formulary and health plan design
por: Ferries, Erin A, et al.
Publicado: (2021) -
Use of Expedited Regulatory Programs and Clinical Development Times for FDA-Approved Novel Therapeutics
por: Wong, Alissa K., et al.
Publicado: (2023) -
What the Proportional Recovery Rule Is (and Is Not): Methodological and Statistical Considerations
por: Kundert, Robinson, et al.
Publicado: (2019) -
Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study
por: Kesselheim, Aaron S, et al.
Publicado: (2015)